Notably, we found that WFDC1 expression was particularly elevated in patients with the RUNX1-RUNX1T1 fusion, suggesting its potential role as a subtype-specific biomarker or therapeutic target in this AML subgroup. Here, RUNX1T1 is linked to acute myeloid leukemia.